Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04074746
What this trial is testing

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
M.D. Anderson Cancer Center 45
Early research (Phase 1)Study completedNCT00005813
What this trial is testing

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

Who this might be right for
Brain and Central Nervous System Tumors
Dartmouth-Hitchcock Medical Center
Early research (Phase 1)Looking for participantsNCT06095089
What this trial is testing

JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 355
Early research (Phase 1)Looking for participantsNCT06515613
What this trial is testing

CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Who this might be right for
Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer
Context Therapeutics Inc. 156
Early research (Phase 1)UnknownNCT05650385
What this trial is testing

B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Who this might be right for
Neoplasms Malignant
Tasly Biopharmaceuticals Co., Ltd. 68
Testing effectiveness (Phase 2)Looking for participantsNCT07348055
What this trial is testing

GR1803 in Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 44
Early research (Phase 1)Active Not RecruitingNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 100
Testing effectiveness (Phase 2)Ended earlyNCT03860207
What this trial is testing

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Who this might be right for
NeuroblastomaOsteosarcomaOther Solid Tumor Cancers
Y-mAbs Therapeutics 12
Early research (Phase 1)Ended earlyNCT04156100
What this trial is testing

A Study in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Agenus Inc. 19
Testing effectiveness (Phase 2)Ended earlyNCT03440437
What this trial is testing

FS118 in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and Neck
invoX Pharma Limited 80
Testing effectiveness (Phase 2)Ended earlyNCT00522457
What this trial is testing

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Neovii Biotech 19
Early research (Phase 1)Looking for participantsNCT07606612
What this trial is testing

SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 31
Not applicableAvailableNCT05119257
What this trial is testing

(Bispecific) Antibodies in Cancer Patients

Who this might be right for
Cancer
University Hospital Tuebingen
Not applicableLooking for participantsNCT06846905
What this trial is testing

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Who this might be right for
Multiple Myeloma in Relapse
University Hospital, Toulouse 40
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06432296
What this trial is testing

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Who this might be right for
Malignant Ascites
Wuhan YZY Biopharma Co., Ltd. 312
Testing effectiveness (Phase 2)Looking for participantsNCT06959550
What this trial is testing

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
M.D. Anderson Cancer Center 90
Testing effectiveness (Phase 2)UnknownNCT03797391
What this trial is testing

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Who this might be right for
NeoplasmsNeoplasm MetastasisNon-Small-Cell Lung Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd. 186
Testing effectiveness (Phase 2)Ended earlyNCT05660967
What this trial is testing

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 111
Testing effectiveness (Phase 2)Ended earlyNCT04618393
What this trial is testing

EMB-02 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd. 47
Next Page